CASE STUDY | ADVERTISING
When Perception Limited Growth, We Redefined the Market.
THE CHALLENGE
Overcoming Constrained Market Perception to Unlock Broader Relevance
A leading global pharmaceutical company was facing increasing competitive pressure within a highly competitive cardio-metabolic therapeutic area. While the product was widely recognized in the market, its perceived value had become narrowly defined around one important benefit.
This constrained perception limited relevance across broader patient populations who could benefit from the therapy’s full clinical profile, including its impact on glycemic control, weight management, and cardiovascular risk. At the same time, a competitor was increasing pressure on the brand, threatening long-term growth potential.
To sustain leadership, the brand needed to expand beyond its established positioning and strengthen relevance across a broader clinical and patient landscape.
THE BREAKTHROUGH
Redefining the Therapy’s Role Across Cardio-Metabolic Risk Factors
BGBx identified that the barrier to increased adoption was not awareness, but entrenched clinical perception. The therapy was narrowly associated with a single outcome, limiting recognition of its broader clinical value. The breakthrough repositioned the brand as a multi-dimensional therapy addressing interconnected cardio-metabolic risk factors
Using our proprietary Breakthrough Process, powered by 3D Science, we validated strategy at every stage of development. Hypotheses were tested against market realities, strategic concepts were validated with target audiences, and creative execution was proven before scaling investment. This reshaped perception and expanded consideration across HCP and patient audiences. A unified brand platform reinforced value across multiple clinical outcomes.
The approach integrated:
- Patient storytelling with real-world profiles to increase relevance
- HCP engagement materials reinforcing expanded clinical use and patient applicability
- Payer and access integration to align across the full decision ecosystem
- Omnichannel activation across TV, digital, social, and HCP channels
- Coordinated communications to extend positioning beyond a single outcom
This coordinated effort expanded clinical relevance and strengthened how the therapy was understood across stakeholders.
THE RESULTS
Expanded Relevance Driving Adoption and Engagement
- Strengthened brand impact through high-performing, differentiated messaging
- Expanded visibility across both patient and healthcare provider audiences
- Increased physician-led discussions focused on cardiovascular risk
- Supported continued growth and strong market share within a highly competitive therapeutic category
The result was a measurable shift in how the therapy was perceived, expanding its clinical relevance beyond a single outcome.
96%
Brand Linkage
Record-breaking
TV performance
230M Audience Impressions
Expanded patient and
provider reach
+20%
Physician Discussions
Increased focus on
cardiovascular risk
Our Perspectives on Advertising

2026 Oncology Market Access Trends

Implications of the IRA’s Maximum Fair Price (MFP) Negotiations

340B Drug Discount Program
Leading the Conversation iLorim Ipsum
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.


